Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Solid Cancers|Colorectal Cancer|Breast Cancer|Non-Small Cell Lung Cancer|Gastrointestinal Cancer|Ovarian Cancer|Genitourinary Cancer
Interventions: DRUG: Aldesleukin|DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: KRAS TCR-Transduced PBL|BIOLOGICAL: GRT-C903/GRT-R904
Sponsor: National Cancer Institute (NCI)